塑生模 碧生源控股有限公司 Besunyen Holdings Company Limited (於開曼群島註冊成立的有限公司) 股份代號: 926 2024 中期報告 型在线 gall 牌元帝 整安夜 list a 整维农 He 2 对目记录 纤纤弹 整生夜 帶青帘 (出荷华版) Ham 整生液 留唐 出張印影:如图漫画 精髓쥬 公司簡介 碧生源控股有限公司（「本公司」）成立於二零零零年九月，二零一零年九月於香港聯交所主板上市（股票 代碼為HK00926）。碧生源控股有限公司及其附屬公司（統稱「本集團」）乃中華人民共和國（「中國」）功能保 健茶的領先供應商，主要從事保健品的研究開發、生產及藥品、食品的銷售及推廣業務。本集團以「一豎 兩橫」為指導方針：一豎是指聚焦在草本植物與健康養生；兩橫是指在「減肥與體重管理」及「潤腸通便與 胃腸道健康」的領域上延展新事業。二十多年來，本集團本著「草本健康，功能好茶」的理念生產與銷售碧 生源牌常潤茶和碧生源牌常菁茶（原名「碧生源牌減肥茶」）（統稱「兩茶」）。本集團持續深耕兩茶業務並陸 續推出碧生源牌纖纖茶、碧生源牌清源茶（與兩茶統稱「四茶」）等系列功能茶產品。近年來，本集團 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 碧生源控股有限公 司 （於開曼群島註冊成立的有限公司） BESUNYEN HOLDINGS COMPANY LIMITED （股份代號：926） 中期業績公告 截至二零二四年六月三十日止六個月 | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ...

2023 年 報 （於開曼群島註冊成立的有限公司） 股份代號: 926 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 全年業績公告 截至二零二三年十二月三十一日止年度 – 1 – – 2 – 綜合全面收益表 – 3 – 已終止經營業務 已終止經營業務年內虧損 9 (198,409) (27,820) 以下各方應佔： 本公司擁有人 — 持續經營業務 (159,105) (76,569) — 已終止經營業務 (140,138) (22,520) 非控股權益 — 持續經營業務 — — — 已終止經營業務 (58,271) (5,300) 年內本公司擁有人應佔每股虧損（人民幣元）： 每股基本虧損 — 持續經營業務 6 (1.30) (1.36) — 已終止經營業務 6 (1.15) (0.40) 每股攤薄虧損 — 持續經營業務 6 (1.30) (1.36) — 已終止經營業務 6 (1.15) (0.40) – 4 – – 5 – | --- | --- | --- | --- | |-------------------- ...

Financial Performance - The group's operating expenses for the first half of 2023 amounted to RMB 222.6 million, a decrease of 1.4% compared to RMB 225.7 million in the same period of 2022[10] - The group's gross profit from continuing operations for the first half of 2023 was RMB 222.2 million, a decrease of 8.3% compared to RMB 242.3 million in the same period of 2022[23] - The group's gross profit margin from continuing operations for the first half of 2023 was 64.8%, an increase of 4.8 percentage points compared to 60.0% in the same period of 2022[23] - The company's attributable comprehensive loss for the first half of 2023 was RMB 116.2 million, with a comprehensive income from continuing operations of RMB 1.3 million and a comprehensive loss from discontinued operations of RMB 117.5 million[24] - The company's revenue from continuing operations in the first half of 2023 was RMB 343.0 million, a decrease of 15.1% compared to the same period in 2022[32] - The company's total comprehensive loss for the first half of 2023 was RMB 174.5 million, with a comprehensive income from continuing operations of RMB 1.3 million and a comprehensive loss from discontinued operations of RMB 175.8 million[33] - The company's revenue in the first half of 2023 was RMB 343.0 million, a year-on-year decrease of 15.1%, with revenue from "Four Teas" at RMB 163.4 million (down 3.9%) and revenue from weight-loss drugs at RMB 116.2 million (down 3.1%)[35] - Sales cost for the first half of 2023 was RMB 120,827 thousand, compared to RMB 161,487 thousand in the same period of 2022[103] - Gross profit for the first half of 2023 was RMB 222,160 thousand, with a gross margin of 64.8%, up from 60.0% in 2022[103] - Sales and marketing expenses for the first half of 2023 were RMB 162.1 million, almost unchanged from RMB 162.4 million in 2022[104] - Employee benefits expenses decreased by RMB 6.6 million in the first half of 2023 compared to the same period in 2022, mainly due to a reduction in sales staff[105] - R&D costs for the first half of 2023 were RMB 18,609 thousand, accounting for 5.4% of revenue, up from 1.0% in 2022[107] - Total revenue for 2023 was RMB 342.987 million, a decrease from RMB 403.774 million in 2022[128] - Revenue from weight loss products in 2023 was RMB 116.184 million, accounting for 33.9% of total revenue, down 3.1% from 2022[128][129] - Revenue from other health products in 2023 was RMB 54.313 million, a significant decrease of 28.9% from 2022[128][129] - Marketing and promotional expenses in 2023 were RMB 66.251 million, a decrease of RMB 10.7 million from 2022, mainly due to reduced e-commerce platform promotion fees[131] - Administrative expenses in 2023 were RMB 41.8 million, a 29.3% decrease from 2022, driven by cost optimization and organizational restructuring[133] - The company's asset-liability ratio as of June 30, 2023, was 19.0%, down from 31.5% at the end of 2022[145] - The company sold 51% equity in target companies for a total consideration of RMB 137.7 million, resulting in a post-tax loss of RMB 175.8 million from discontinued operations[144] - Employee costs for the first half of 2023 were RMB 81.8 million, down from RMB 95.4 million in the same period in 2022[148] - The company's total inventory as of June 30, 2023, was RMB 35.3 million, a significant decrease from RMB 109.239 million in 2022[143] - Revenue for the first half of 2023 was RMB 343.0 million, a decrease of 15.1% compared to RMB 403.8 million in the same period of 2022[150] - Gross profit margin increased to 64.8% in the first half of 2023, up 4.8 percentage points from 60.0% in the same period of 2022, driven by higher-margin products and reduced procurement costs for weight-loss drugs[151] - Advertising expenses increased by RMB 18.7 million in the first half of 2023 compared to the same period in 2022[152] - R&D costs rose to RMB 18.6 million in the first half of 2023, up from RMB 4.2 million in the same period of 2022, primarily due to outsourced R&D activities[155] - The company recorded a total comprehensive loss of RMB 174.5 million in the first half of 2023, compared to a loss of RMB 9.1 million in the same period of 2022[156] - The company's total comprehensive loss attributable to owners for the six months ended June 30, 2023, was RMB 116,219 thousand, compared to a loss of RMB 6,621 thousand in the same period in 2022[177] - The loss from discontinued operations for the six months ended June 30, 2023, was RMB 117,501 thousand, compared to a loss of RMB 2,591 thousand in the same period in 2022[177] - The company's total assets decreased from RMB 1,537,138 thousand as of December 31, 2022, to RMB 911,200 thousand as of June 30, 2023[179][181] - The company's total liabilities decreased from RMB 484,728 thousand as of December 31, 2022, to RMB 173,082 thousand as of June 30, 2023[181] - The company's total equity decreased from RMB 1,052,410 thousand as of January 1, 2023, to RMB 738,118 thousand as of June 30, 2023[183] - The company's non-current assets decreased from RMB 794,366 thousand as of December 31, 2022, to RMB 334,251 thousand as of June 30, 2023[179] - The company's current assets decreased from RMB 742,772 thousand as of December 31, 2022, to RMB 576,949 thousand as of June 30, 2023[179] - The company's inventory decreased from RMB 109,239 thousand as of December 31, 2022, to RMB 35,300 thousand as of June 30, 2023[179] - The company's cash and cash equivalents increased from RMB 230,320 thousand as of December 31, 2022, to RMB 264,961 thousand as of June 30, 2023[179] - The company's total comprehensive loss for the six months ended June 30, 2023, was RMB 174,490 thousand, compared to a loss of RMB 9,110 thousand in the same period in 2022[183] Sales and Distribution - The group's offline sales business covered nearly 410,000 OTC pharmacies and supermarkets across 31 provinces, autonomous regions, and municipalities through 118 distributors and 98 sub-distributors in the first half of 2023[16] - The group's online sales team operated 120 stores on 36 e-commerce platforms, selling products including the four teas, Orlistat, and other group products in the first half of 2023[16] - The group's offline sales team directly serves nearly 100,000 OTC pharmacies and supermarkets[16] - The group has been actively exploring new retail channels such as Douyin, Kuaishou, O2O, and B2C to accelerate market entry for new products[16] - The company's offline sales business covered nearly 410,000 OTC pharmacies and third terminals across 31 provinces, autonomous regions, and municipalities through 118 distributors and 98 sub-distributors[26] - The company's online sales team operates 120 stores on 36 e-commerce platforms, focusing on products like "Four Teas" and Orlistat[26] - The company is actively exploring new retail models such as TikTok, Kuaishou, O2O, B2C, and cross-border e-commerce to accelerate market entry for new products[26] - The company implemented a "one-row-one-control" promotional marketing campaign in the weight loss and intestinal health product categories, focusing on core and regional key chains[27] - The company leveraged O2O, membership platforms, and live streaming to enhance consumer engagement and increase purchase intent[28] - The company has implemented a strategy to enhance sales through data-driven analysis, focusing on metrics such as distribution rate, number of stores, customer order growth, and single-store productivity[79] - The e-commerce division has improved inventory management, reducing inventory turnover time and minimizing losses from expired products, while also decreasing inventory levels and capital tied up in stock[85] - The company has strengthened platform communication and resource collaboration, securing favorable terms and policy support from platforms like JD.com during major promotions such as 38, 55, and 618[87] - The company has leveraged high-speed rail media to enhance brand influence, focusing on short-term high exposure strategies to rapidly cover target markets and boost brand momentum[90] - The company has targeted the family demographic in the new retail era, aiming to capture growth opportunities in lower-tier markets[92] - The company has engaged with Generation Z through campus activities and collaborations with academic institutions, promoting a healthy lifestyle and gathering creative insights for product development and marketing[94] - The company achieved a closed-loop operation system for product promotion and sales on the Douyin platform, enhancing the effectiveness of platform promotion and acquiring more high-quality new customers[114] - The company expanded its e-commerce channels by adding Baidu Health Mall and Dewu platform in the first half of 2023[115] - The company collaborated with China High-Speed Rail to reach a large number of passengers and release brand potential[118] Research and Development - The group has 38 health food approvals and 116 patented technologies, including 18 invention patents[4] - The group's production base for the four teas is located in Beijing's Fangshan District, with facilities and processes compliant with national GMP standards and certified by ISO9001, ISO22000, and HACCP systems[15] - The company completed the national key R&D project on the evaluation system and demonstration research platform for traditional Chinese medicine health products[95] - The company completed the development and academic research of a new product, Poria and Alisma Tablets, with weight-loss health functions[124] - The company plans to focus on R&D, market trends, and consumer demand, particularly in weight management and gastrointestinal health, while exploring new retail channels[127] Corporate Governance and Shareholding - Executive Director Zhao Yihong holds a 51.34% beneficial interest in the company's shares, including direct and indirect holdings through controlled entities[48][49] - Foreshore Holding Group Limited, controlled by Zhao Yihong, holds a 50.07% stake in the company's issued shares[54] - Peng Wei, a major shareholder, holds an 8.41% stake in the company's issued shares[54] - Everyoung Investment Holdings Limited, controlled by Peng Wei, holds a 7.59% stake in the company's issued shares[54] - The company's total issued shares as of June 30, 2023, amounted to 122,265,585 shares[56] - The company's board has decided not to declare any dividends for the six months ended June 30, 2023[63] Operational Efficiency and Cost Management - The company is optimizing its organizational structure and product portfolio to improve operational efficiency and profitability[35] - The company's wage, bonus, and other allowances expenses for the six months ended June 30, 2023, totaled RMB 4,687,000[68] - The company's pension costs for the six months ended June 30, 2023, amounted to RMB 143,000[68] - The company's total employee benefits expenses for the six months ended June 30, 2023, were RMB 4,830,000[68] - The company has signed non-cancellable operating leases for offices and staff dormitories, with future minimum lease payments not recognized as liabilities on the balance sheet[70] - The company's capital commitments for property, plant, and equipment as of June 30, 2023, amounted to RMB 7,211,000[69] - Capital expenditures for property, plant, and equipment totaled RMB 3.2 million in the first half of 2023, down from RMB 11.4 million in the same period of 2022[164] - Inventory levels decreased significantly, with finished goods inventory dropping to RMB 28.8 million as of June 30, 2023, from RMB 59.8 million as of December 31, 2022[166] - The company utilized RMB 125.9 million from a rights issue for its intended purposes as of June 30, 2023[163] - Capital commitments for property, plant, and equipment stood at RMB 7.2 million as of June 30, 2023, down from RMB 12.6 million as of December 31, 2022[195] - The company allocated funds for investments in funds and other financial assets to generate investment income while maintaining liquidity[194] Cash Flow and Financial Position - Cash and cash equivalents, including time deposits, amounted to RMB 377.9 million as of June 30, 2023, down from RMB 483.8 million as of December 31, 2022[161] - Bank borrowings decreased to RMB 5.0 million as of June 30, 2023, with an interest rate of 4.70%, compared to RMB 177.6 million as of December 31, 2022[162] - Operating cash flow from continuing operations increased to RMB 44,126 thousand in H1 2023, compared to a negative RMB 52,704 thousand in H1 2022[185] - Net cash inflow from operating activities reached RMB 88,197 thousand in H1 2023, a significant improvement from RMB 9,505 thousand in H1 2022[185] - Proceeds from the sale of financial assets at fair value through profit or loss amounted to RMB 263,170 thousand in H1 2023, slightly lower than RMB 411,898 thousand in H1 2022[185] - Net cash inflow from investing activities decreased to RMB 18,013 thousand in H1 2023 from RMB 85,016 thousand in H1 2022[185] - Net cash outflow from financing activities was RMB 71,313 thousand in H1 2023, higher than RMB 49,463 thousand in H1 2022[185] Sustainability and Corporate Responsibility - The company emphasized sustainable development, employee welfare, and maintaining strong relationships with suppliers and customers[197] - The company invested in employee education and training programs to enhance skills and collaboration[198] Financial Reporting Standards - The interim financial information was prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting"[200]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 碧 生 源 控 股 有 限 公司 BESUNYEN HOLDINGS COMPANY LIMITED （於開曼群島註冊成立的有限公司） （股份代號：926） 中期業績公告 截至二零二三年六月三十日止六個月 本集團的經營業績 本集團二零二三年上半年的持續經營業務收入為人民幣343.0百萬元，較二零二二年同 期的持續經營業務收入人民幣403.8百萬元減少15.1%。 本集團二零二三年上半年的持續經營業務毛利為人民幣222.2百萬元，較二零二二年同 期的持續經營業務毛利人民幣242.3百萬元減少8.3%。本集團二零二三年上半年的持續 經營業務毛利率為64.8%，較二零二二年同期的持續經營業務毛利率60.0%上升4.8個百 分點。 本集團二零二三年上半年持續經營業務的運營開支（包括銷售及市場營銷開支、行政開 ...

碧生源控股有限公司 年 報 2022 （於開曼群島註冊成立的有限公司） 股份代號: 926 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 碧 生 源 控 股 有 限 公司 BESUNYEN HOLDINGS COMPANY LIMITED （於開曼群島註冊成立的有限公司） （股份代號：926） 全年業績公告 截至二零二二年十二月三十一日止年度 財務摘要 於二零二二年，本集團的收入約為人民幣943.3百萬元，較二零二一年的收入約人民幣 1,101.2百萬元下降約14.3%。 於二零二二年，本集團的毛利率為60%，較二零二一年的63.4%下降3.4個百分點。 於二零二二年，本集團錄得全面虧損總額約為人民幣104.4百萬元，較二零二一年全面 虧損總額約人民幣114.0百萬元減少虧損約8.4%。 於二零二二年，每股基本及攤薄虧損約為人民幣1.76元，而二零二一年每股基本及攤薄 虧損約為人民幣3.65元。 ...

塑生模 碧生源控股有限公司 Besunyen Holdings Company Limited (於開曼群島註冊成立的有限公司) 股份代號: 926 2022 中 期 報 告 � | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------ ...

塑生模 碧生源控股有限公司 Besunyen Holdings Company Limited (於開曼群島註冊成立的有限公司) 股份代號: 926 Besunyen 年 報 2021 青帘 20 71 5 分 公司簡介 碧生源控股有限公司（「本公司」）及其附屬公司 （統稱「本集團」）乃中華人民共和國（「中國」）功 能保健茶的領先供應商，主要從事功能保健茶 及藥品的研究開發、生產、銷售及推廣業務。 二十年來，本集團本著「草本健康，功能好茶」 的理念生產碧生源牌常潤茶和碧生源牌常菁茶 （原名「碧生源牌減肥茶」）（統稱「兩茶」），近幾 年，本公司持續深耕兩茶業務並陸續推出碧生 源牌纖纖茶（與兩茶統稱「三茶」）等系列功能茶 產品。截至二零二一年十二月三十一日，三茶 累計銷量突破55.85億袋，累計銷售額超過人民 幣74.94億元。本集團自二零一五年四月開始銷 售來利牌奧利司他減肥膠囊，二零一七年十月 收購中山萬漢製藥有限公司（「中山萬漢」）及中 山 萬 遠 新 藥 研 發 有 限 公 司（「中山萬遠」，合 稱 「中山萬漢萬遠」），中 山 萬 漢 萬 遠 的 主 要 業 務 為研發、生產及銷售碧生源牌奧利司他減肥膠 ...